Introduction
============

Plasma amino acids and carnitine levels have a close relationship with protein metabolism and body nutrition, which can reflect the level of protein metabolism. They also act as indicators to evaluate the nutritional status. Plasma amino acid and carnitine concentrations have to be maintained at a certain level under normal conditions. Any fluctuation in the normal level indicates diseased states or some special physiological condition. This study used liquid chromatography--tandem mass spectrometry (LC--MS/MS) and isotope labeling methods to determine the levels of carnitine and plasma amino acids in malignant tumor patients undergoing chemotherapy and in healthy people (control). The study was aimed at observing the change in the levels of plasma amino acids and carnitine in advanced malignant tumor patients. This study also provides a scientific basis for clinical nutrition monitoring and reasonable nutrition support for patients with malignant tumor. The study also aims to observe the influence of hypocarnitinemia and citrullinemia on chemotherapy and provide a scientific method to improve the efficiency of chemotherapy in diseased people.

Materials and methods
=====================

Materials
---------

Thirty gastrointestinal cancer patients (18 men and 12 women) undergoing chemotherapy in our hospital were selected. The study was approved by the Institutional Review Board (CWO) of The First Affiliated Hospital of Liaoning Medical University. All patients provided written informed consent for the use of their data. Among the patients included, seven were suffering with gastric carcinoma, ten with rectal cancer, and 13 with colon cancer. The median age was 55.27 years. All the patients had stage IV gastrointestinal malignant tumors before chemotherapy, which was confirmed by pathology and imaging.[@b1-ott-8-1989] They were given XELOX chemotherapy. Control group included 30 healthy people (15 men and 15 women) who came to our hospital for physical examination, and the median age was 53.91 years. The median weight and height of the patients were 51 kg and 158 cm, respectively. The median weight and height of the healthy people (control group) were 60 kg and 160 cm, respectively. There were no differences between the two groups regarding age, weight, and height (*P*\>0.05).

Methods
-------

### Chemotherapy methods

Chemotherapy regimen used for treatment was as follows: XELOX scheme chemotherapy (L-OHP \[oxaliplatin\] 130 mg/m^2^·dL + Xeloda \[capecitabine\] 1,800 mg/m^2^ po (orally), days 1--14, q21d \[every 21 days\]).[@b2-ott-8-1989]

#### Specimens

Patient's specimens were collected at four time points: before chemotherapy, 1 day after chemotherapy, 14 days after chemotherapy (myelosuppression period), and 21 days after chemotherapy (post-chemotherapy recovery period). Four milliliters of fasting peripheral blood of each patient was collected, anticoagulated by heparin, and separated from plasma within 30 minutes by centrifugation (10,000 rpm for 10 minutes). After centrifugation, the plasma was transferred to clean epoxy resin (EP) tubes, refrigerated at 20°C, and tested in batches. Plasma amino acids and carnitine were analyzed at the four time points. Blood biochemical indexes including serum hemoglobin (Hb), serum albumin (ALB), aspartate transaminase (AST), and alanine transaminase (ALT) were also detected ([Table 1](#t1-ott-8-1989){ref-type="table"}).

#### Specimen processing

About 10 µL of sample was taken in 1.5 ml EP tube and 100 µL of daily working liquid was added. Then, it was centrifuged at 13,200 rpm for 2 minutes. Centrifugal supernatant was directly transferred to another 1.5 mL EP tube, which was dried at 50°C under nitrogen protection. After adding 60 µL of derivatization reagent, the tube was sealed and vibrated on a vortex mixer for 30 seconds. Then, the solution was immediately centrifuged and incubated at 65°C for 15 minutes, for derivatization to occur. The derived solution was centrifuged again and dried at 50°C under nitrogen protection. Then, it was centrifuged again and incubated at 65°C for 15 minutes, for derivatization to occur. The derived solution was centrifuged again, and was dried at 50°C under nitrogen protection. Then, 100 µL of reconstitution fluid was added, vibrated on a vortex mixer for 30 seconds, and centrifuged at 13,200 rpm for 2 minutes. About 5 µL of the sample was analyzed by LC-MS/MS.

#### Experimental apparatus

Experimental apparatus consisted of 3200QTRAP liquid chromatography--tandem mass spectrometer equipped with electrospray ionization source and Analyst 1.5 data processing software (Applied Biosystem Company, Foster City, CA, USA), UltiMate3000 standard liquid chromatography system, including double ternary gradient pump, automatic sampler, column temperature box, switch valve(America Diane Company), and nitrogen enrichment apparatus(Tokyo Physical and Chemical Equipment Co., Tokyo, Japan).

#### Chromatographic conditions

Chromataographic conditions were as follows: TC: C18 column, 150 mm×4.6 mm ID (Agilent Technologies, Santa Clara, CA, USA); mobile phase: acetonitrile--water, gradient elution; column temperature: 50°C; sample quantity: 5 µL.

The adverse reactions that occurred during chemotherapy were recorded. RR was assessed by imaging examination. One-year follow-up was done for time to progression (TTP) and progression-free survival (PFS).

Statistical analysis
--------------------

The data were analyzed using SPSS 19.0 statistical software. Non-normal distribution measurement data used " $\overline{x} \pm S\ \overline{x}$" and showed that according to the three digestive tract malignant tumors, multiple sets were compared by the independent sample Kruskal--Wallis H test (*P*\>0.05 indicated no statistically significant difference). Normal distribution measurement data used ' $\overline{x} \pm S$' and showed that, according to the chemotherapy time points, multiple sets were compared and analyzed by variance analysis and Bonferroni test. *T*-test was used to analyze AST, ALT, TTP, PFS, hypocarnitinemia, and citrullinemia among tumor patients and control group. Chi-square analysis was used to analyze RR and adverse reactions of chemotherapy. *P*\<0.05 indicated statistically significant difference.

Ethics statement
----------------

The study was approved by the institutional review board (CWO) of The First Affiliated Hospital of Liaoning Medical University. All patients provided written informed consent for the use of their data.

Results
=======

Biochemical changes in each period of intensive chemotherapy in patients with alimentary canal malignancies
-----------------------------------------------------------------------------------------------------------

This study showed that HB and ALB levels of the digestive tract malignant tumor patients dropped significantly compared to control group during chemotherapy (*P*\<0.05) ([Table 1](#t1-ott-8-1989){ref-type="table"}). HB and ALB reached a minimum level 14 days after chemotherapy compared to pre-chemotherapy (*P*\<0.05). The values of HB and ALB at 21 days after chemotherapy (hematopoietic recovery) were close to those present before chemotherapy (*P*\<0.05). AST and ALT levels had significantly increased during chemotherapy compared with control group (*P*\<0.05). AST and ALT levels were the highest at 14 days after chemotherapy compared with pre-chemotherapy values (*P*\<0.05). AST and ALT levels at 21 days after chemotherapy (hematopoietic recovery) dropped down and were close to those at pre-chemotherapy (*P*\<0.05).

Plasma amino acids before chemotherapy in patients with metastatic alimentary canal malignancies
------------------------------------------------------------------------------------------------

This study showed that the plasma amino acids and carnitine spectrum of gastric cancer, rectal cancer, and colon cancer before chemotherapy were clearly different, including asparaginate (Asn), leucine (Leu), piperamide (Pip), and free carnitine (C0) (*P*\<0.05). The other amino acids and carnitine spectrum showed no significant difference (*P*\>0.05) ([Table 2](#t2-ott-8-1989){ref-type="table"}).

Plasma amino acids in each period of intensive chemotherapy in patients with alimentary canal malignancies
----------------------------------------------------------------------------------------------------------

A significant increase in the levels of a few plasma amino acids and carnitine, which included arginine (Arg), asparagine (Asp), citrulline (Cit), glycine (Gly), ornithine (Orn), tyrosine (Tyr), valine (Val), and acetyl-l-carnitine (C2), was observed in the digestive tract malignant tumor patients before chemotherapy compared to control group (*P*\<0.05). But the levels of some plasma amino acids and carnitine, which included propionyl-carnitine (C3), Asn, Leu, lysine (Lys), Pip, proline (Pro), C0, and pentene acyl carnitine (C5:1), decreased significantly (*P*\<0.05). The levels of the remaining amino acids and carnitine showed no statistical significance compared to the control group.

The levels of some plasma amino acids and carnitine, including Cit, cysteine (Cys), Lys, Pro, Tyr, Val, C0, and C2, of the digestive tract malignant tumor patients 1 day after chemotherapy were shown to decrease significantly, but the C3 level showed a significant rise (*P*\< 0.05) compared to healthy control group. The levels of some plasma amino acids, such as Asp, Cit, methionine (Met), and Orn, and carnitine of the digestive tract malignant tumor patients decreased significantly (*P*\<0.05) 14 days after chemotherapy, whereas the level of Val presented an increasing trend (*P*\< 0.05) ([Table 3](#t3-ott-8-1989){ref-type="table"}).

AST, ALT, TTP, PFS, RR, and adverse reactions in eight patients with hypocarnitinemia compared with control group during chemotherapy
-------------------------------------------------------------------------------------------------------------------------------------

This study showed that AST and ALT levels of eight patients with hypocarnitinemia were significantly higher than those of the control group (*P*\<0.05), while the mTTP (the median TTP), PFS, and RR were lower than those of the control group (*P*\<0.05). The occurrence of adverse reactions such as diarrhea, nausea, vomiting, and myelosuppression showed no significant difference in the control group (*P*\>0.05) ([Tables 4](#t4-ott-8-1989){ref-type="table"} and [5](#t5-ott-8-1989){ref-type="table"}).

AST, ALT, TTP, PFS, RR, and adverse reactions in 12 patients with hypercitrullinemia compared with control group during chemotherapy
------------------------------------------------------------------------------------------------------------------------------------

No obvious difference was found in the levels of AST, ALT, TTP, PFS, and RR in 12 patients with hypercitrullinemia compared to the control group. The occurrence of adverse reactions such as diarrhea, nausea, vomiting, and myelosuppression also showed no significant difference (*P*\>0.05) ([Tables 6](#t6-ott-8-1989){ref-type="table"} and [7](#t7-ott-8-1989){ref-type="table"}).

Discussion
==========

At present, there are few reports on the dynamic monitoring of the change and relationships in serum albumin, plasma amino acids, and carnitines of the gastrointestinal malignancies during chemotherapy. This research used the advanced LC--MS/MS to detect the samples. The analysis process of the LC--MS/MS included ionizing molecules to be detected, separating ions according to mass-to-charge ratio (m/z), and detecting various ions with a set of scan modes. LC-MS/MS could be used to detect dozens of metabolites present in the body both qualitatively and quantitatively.[@b3-ott-8-1989],[@b4-ott-8-1989] The metabolic state of the body and its variation, and amino acids, organic acids, fatty acids, free carnitine, and acyl carnitine metabolism could also be evaluated by this method.[@b5-ott-8-1989] This study used the advanced technology that is generally used to screen genetic metabolic diseases in newborns, to analyze amino acid and carnitine metabolism changes and prognosis of tumor patients.

This study evaluated 30 patients with stage IV gastrointestinal malignant tumors before chemotherapy, who were not able to undergo operation. Significant differences in the levels of Asn, Leu, Pip, and C0 were observed in three patients with digestive tract malignant tumor before chemotherapy (*P*\<0.05). Among the gastric cancer patients, Asn was observed to be the highest, Leu and Pip the highest among colorectal cancer patients, and C0 the highest among the colon cancer patients. The study showed that all the three types of digestive tract malignant tumors had different impact on the nutritional status of patients, and hence Leu, Pip, and C0 are considered as significant markers for the identification of digestive tract malignant tumor.

This study showed that patients' serum albumin level before chemotherapy decreased significantly compared to normal level, fell to the lowest level at 14 days after chemotherapy, and recovered close to normal level at 21 days after chemotherapy; a similar change was also observed for plasma amino acids. In the case of malnutrition, low concentration of albumin level was not due to the descending liver ability to synthesize proteins, but because of the lack of nutrients required for amino acid synthesis in the body.[@b6-ott-8-1989],[@b7-ott-8-1989] Serum albumin level often acts as an index to evaluate malnutrition in clinical settings, but the change period is longer than that of plasma amino acids. Hence, monitoring plasma amino acid levels indicates patients' nutritional status and the effect of nutritional support, in time.

Carnitine is a quaternary ammonium compound biosynthesized from amino acids. It contains a left-handed and a right-handed form, but only [l]{.smallcaps}-carnitine shows physiological activities.[@b5-ott-8-1989],[@b8-ott-8-1989] Carnitine in the human body is found in two forms: free carnitine and fatty acyl carnitine. Carnitine plays an important role in the oxidation pathway of long chain fatty acids and their transport through mitochondrial membrane.[@b9-ott-8-1989],[@b10-ott-8-1989] Excess acyl formed due to oxidation and carnitine can result in the formation of acyl carnitine.[@b11-ott-8-1989] Free acyl can inhibit the cell enzyme activity, which can cause metabolic acidosis. So carnitine is an indispensable compound to energy metabolism.[@b12-ott-8-1989],[@b13-ott-8-1989]

At present no clear reports are available that emphasize the relationship of amino acid and carnitine spectral changes with the digestive tract malignant tumors. This study shows that the levels of both free and total carnitine of the digestive tract malignant tumor patients are lower than the control group. Levels of free carnitine fall further after chemotherapy, and this indirectly affects the function of liver. This might be associated with the inhibition of mitochondrial oxidation caused by tumor cells. The abnormality in cell energy results in cell damage, whereas energy metabolism of normal cells is enhanced so that carnitines are further consumed. As a result, the carnitine levels of tumor patients are lower than the normal individuals. Levels of free carnitine fall further during chemotherapy, which may be related to the limited reserve of carnitine. Much of carnitine is lost during chemotherapy due to diarrhea, nausea, vomiting, and loss of appetite, which results in hypocarnitinemia.

This study also found that TTP, PFS, and RR of patients with hypocarnitinemia were lower compared to normal chemotherapy patients, which illustrated that patients with hypocarnitinemia were not sensitive to chemotherapy and had low treatment efficacy and poor prognosis. C2 of patients with hypocarnitinemia was higher than normal, which was because long-chain acyl carnitine was mainly oxidized in mitochondria,[@b14-ott-8-1989] and the oxidation process could be affected by tumors. Because of a lack of carnitine acyl transferase, ester acyl exchange disorder occurred for the accumulation of acyl coenzyme A. A series of adverse complications, including liver damage, was also observed. So hypocarnitinemia is a poor prognosis factor of digestive tract malignant tumor. People can improve treatment efficacy and quality of life by taking carnitine.

This study found that the citrulline level of the digestive tract malignant tumor patients was higher compared to control group. Citrulline plays an important role in the urea cycle. Citrulline is produced from blood ammonia by the action of enzymes, and then is transported out of the mitochondria. Citrulline combines with aspartic acid to form pure ammonia acyl succinic acid in the presence of ammonia acyl succinyl synthetase.[@b15-ott-8-1989] Presence of high citrulline level indicates urea cycle disorder and accumulation of large amounts of blood ammonia in the body, which may cause damage to the liver.[@b16-ott-8-1989] No significant difference was noted in factors such as AST, ALT, TTP, PFS, RR, diarrhea, nausea, vomiting, and myelosuppression due to hypercitrullinemia compared with normal chemotherapy group.

Glutamine was found to be significantly lower in tumor patients compared to control group during the whole chemotherapy period (including recovery period) ([Table 3](#t3-ott-8-1989){ref-type="table"}) and nearly fourfold lower than pre-chemotherapy period. Reasons for the significant decrease in glutamine include loss of appetite caused by capecitabine, inadequate intake or absorption of basic amino acids, and inadequate intake of total amino acids. Glutamine can improve the body's metabolism, increase the total number of lymphocytes, and improve the body's immune status and oxidation resistance.[@b17-ott-8-1989] Lack of glutamine results in decreased immune function after chemotherapy, increased intestinal mucosal permeability, secondary bacterial translocation, and systemic infection.[@b18-ott-8-1989] This might be the cause of aggravating diarrhea after oral capecitabine. Hence patients are advised to take sufficient glutamine supplements before chemotherapy so as to maintain their nutritional status and improve their immune levels during the disease period.

In summary, as two of the nutritional assessment index, amino acid spectrum and carnitine spectrum can indicate the patients' nutritional status much earlier and help to provide required nutritional support. Analysis of these spectrums showed abnormal levels of free carnitine, citrulline, glutamine, and essential amino acids in tumor patients compared to control group. The abnormality not only leads to systemic metabolic disorder but also affects all of the plasma amino acids, trace nutrients, and vitamins. Monitoring of amino acids and carnitine spectrum can provide some references and guidance for chemotherapy regimens and nutrition therapy. Patients with malignant tumors should be encouraged to take enteral nutrition, vitamins, and trace elements much earlier to overcome the metabolic disorder. Moreover, it reduces the nutritional risk caused by digestive tract infection, mucosal inflammation, fever, diarrhea and other complications during the chemotherapy.

This study also showed that tandem mass spectrometry can be used to detect blood amino acids and carnitine spectrum may be used for an early diagnosis and in the evaluation of adverse reactions and prognosis of the digestive tract malignant tumor patients. Long-term follow-up of all the tumor patients was not possible in this study due to limited time and funds. More clinical research is necessary to study the significance of blood amino acids and carnitine spectrum in detecting digestive tract malignant tumors in the future.
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###### 

Biochemical changes in each period of intensive chemotherapy in patients with alimentary canal malignancies

  Biochemical index                                 Hb                                                                                                AST                                                                                               ALT                                                                                               ALB
  ------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Control group (n=30)                              129.13±17.78                                                                                      28.16±12.49                                                                                       36.53±13.59                                                                                       48.13±4.98
  Before chemotherapy (n=30)                        120±15.52                                                                                         33.66±12.45                                                                                       52.73±27.95                                                                                       44.62±5.57
  The first day after chemotherapy (+1 day, n=30)   112.33±19.22[a](#tfn1-ott-8-1989){ref-type="table-fn"}                                            43.8±20.38                                                                                        69.73±33.01[a](#tfn1-ott-8-1989){ref-type="table-fn"}                                             40.77±5.21[a](#tfn1-ott-8-1989){ref-type="table-fn"}
  Bone marrow depression period (+14 days, n=30)    102.2±15.61[a](#tfn1-ott-8-1989){ref-type="table-fn"}[b](#tfn2-ott-8-1989){ref-type="table-fn"}   61.23±28.50[a](#tfn1-ott-8-1989){ref-type="table-fn"}[b](#tfn2-ott-8-1989){ref-type="table-fn"}   87.13±36.03[a](#tfn1-ott-8-1989){ref-type="table-fn"}[b](#tfn2-ott-8-1989){ref-type="table-fn"}   39.29±5.02[a](#tfn1-ott-8-1989){ref-type="table-fn"}[b](#tfn2-ott-8-1989){ref-type="table-fn"}
  Hematopoietic recovery period (+21 days, n=30)    113.63±18.42[a](#tfn1-ott-8-1989){ref-type="table-fn"}                                            48.96±27.36[a](#tfn1-ott-8-1989){ref-type="table-fn"}                                             68.56±41.42[a](#tfn1-ott-8-1989){ref-type="table-fn"}                                             42.66±6.06[a](#tfn1-ott-8-1989){ref-type="table-fn"}

**Notes:**

*P*\<0.05 (significant difference vs the control group);

*P*\<0.05 (significant difference vs before chemotherapy).

**Abbreviations:** Hb, hemoglobin; AST, aspartate transaminase; ALT, alanine transaminase; ALB, albumin.

###### 

Plasma amino acids before chemotherapy in patients with metastatic alimentary canal malignancies ( $\overline{x} \pm S$)

  Amino acids   Gastric carcinoma (n=7)                                  Rectal cancer (n=10)                                     Colon cancer (n=13)
  ------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  C3            2.18±0.36                                                1.99±0.54                                                1.82±0.42
  Arg           65.74±21.31                                              50.46± 19.15                                             73.55±30.07
  Asn           49.77±17.791[a](#tfn4-ott-8-1989){ref-type="table-fn"}   42.31±11.54[a](#tfn4-ott-8-1989){ref-type="table-fn"}    21.93±14.35[a](#tfn4-ott-8-1989){ref-type="table-fn"}
  Asp           120.95±17.88                                             105.78±30.74                                             114.81 ±20.65
  Cit           36.00± 13.47                                             39.21 ±15.85                                             41.81±11.55
  Cys           3.51 ± 1.35                                              3.14±1.11                                                3.03±0.97
  Gln           5.04±3.40                                                8.91 ±9.26                                               7.97±5.24
  Gly           502.19±296.03                                            458.04±238.49                                            355.66± 147.47
  Leu           95.48±64.69[a](#tfn4-ott-8-1989){ref-type="table-fn"}    115.22±84.31[a](#tfn4-ott-8-1989){ref-type="table-fn"}   43.32±22.08[a](#tfn4-ott-8-1989){ref-type="table-fn"}
  Lys           61.25±40.79                                              61.47±23.33                                              48.73±26.65
  Met           53.73±26.70                                              61.46±23.46                                              70.47±29.65
  Orn           191.12±55.16                                             186.23±70.43                                             222.68±80.93
  Pip           41.54± 12.27[a](#tfn4-ott-8-1989){ref-type="table-fn"}   159.57±76.59[a](#tfn4-ott-8-1989){ref-type="table-fn"}   153.49±78.06[a](#tfn4-ott-8-1989){ref-type="table-fn"}
  Pro           196.07±67.00                                             146.93±53.59                                             182.80±66.31
  Ser           78.41 ±40.28                                             41.81 ±34.30                                             42.95±30.31
  Trp           49.64±50.47                                              71.49±41.01                                              52.57±35.05
  Tyr           167.53±36.71                                             196.22±70.34                                             215.08±64.49
  Val           168.56±54.88                                             177.44±74.30                                             215.07±69.43
  C0            21.08±9.68[a](#tfn4-ott-8-1989){ref-type="table-fn"}     15.61±6.51[a](#tfn4-ott-8-1989){ref-type="table-fn"}     28.15±13.47[a](#tfn4-ott-8-1989){ref-type="table-fn"}
  C2            31.21±9.29                                               35.82±11.98                                              42.54±15.53
  C5:1          0.01±0.01                                                0.02±0.01                                                0.02±0.01

**Note:**

*P*\<0.05 (significant difference between groups).

**Abbreviation:** S, standard deviation.

###### 

Plasma amino acids in each period of intensive chemotherapy in patients with alimentary canal malignancies ( $\overline{x} \pm s$)

  Amino acids   Control (n=30)   Before chemotherapy (n=30)                                1 day after chemotherapy (n=30)                                                                    14 days after chemotherapy (n=30)                                                                                                            21 days after chemotherapy (n=30)
  ------------- ---------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  C3            2.85±0.64        1.96±0.46[a](#tfn6-ott-8-1989){ref-type="table-fn"}       38.67±34.45                                                                                        2.58±0.58[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                          2.14±0.53[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Arg           24.34±29.30      64.03±26.21[a](#tfn6-ott-8-1989){ref-type="table-fn"}     2.66±0.45[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                28.88±20.94[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                        60.66±27.14[a](#tfn6-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Asn           67.66± 18.74     35.22±18.43[a](#tfn6-ott-8-1989){ref-type="table-fn"}     26.91±15.74[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                              20.13±13.62[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              27.29± 15.02[a](#tfn6-ott-8-1989){ref-type="table-fn"}
  Asp           49.82±28.25      113.23±23.88[a](#tfn6-ott-8-1989){ref-type="table-fn"}    47.13±23.94[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                              80.10±30.23[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}    119.50±38.79[a](#tfn6-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Cit           25.74±9.92       39.59±13.27[a](#tfn6-ott-8-1989){ref-type="table-fn"}     106.23±33.96[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                             17.05± 11.39[b](#tfn7-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}                                             37.04±17.22[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Cys           3.74±1.56        3.18±1.09                                                 27.00±12.62[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              1.26±0.94[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                2.96± 1.13[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Gln           11.36±6.50       7.60±6.53                                                 2.13± 1.18[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}     3.18±3.41[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                                                                          6.95±5.57[a](#tfn6-ott-8-1989){ref-type="table-fn"}
  Gly           200.12± 103.20   423.98±220.79[a](#tfn6-ott-8-1989){ref-type="table-fn"}   5.37±5.93[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                                203.07± 173.14[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                     430.85±242.99[a](#tfn6-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Leu           84.48±27.19      79.46±66.04[a](#tfn6-ott-8-1989){ref-type="table-fn"}     296.39± 180.83                                                                                     35.87±32.65[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              68.78±58.43[a](#tfn6-ott-8-1989){ref-type="table-fn"}
  Lys           208.33±63.53     55.90±29.12[a](#tfn6-ott-8-1989){ref-type="table-fn"}     54.48±45.52[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                              18.92±19.97[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              53.07±29.73[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Met           46.33±24.59      63.56±26.99                                               33.62±24.15[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}    24.40±21.84[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}    69.00±28.61[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Orn           57.59±53.57      203.17±72.00[a](#tfn6-ott-8-1989){ref-type="table-fn"}    49.59±27.88                                                                                        109.73±65.47[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}   195.29±67.11[a](#tfn6-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Pip           270.77±98.90     129.39±82.52[a](#tfn6-ott-8-1989){ref-type="table-fn"}    167.48±69.32[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                             57.31±54.37[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              135.67±83.62[a](#tfn6-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Pro           261.65±76.77     173.94±63.60[a](#tfn6-ott-8-1989){ref-type="table-fn"}    113.23±43.97[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}   77.21±46.65[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              185.05±60.49[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Ser           77.65±34.83      50.84±36.34                                               91.21±72.88[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                              65.9147±55.07                                                                                                                                47.72±42.79
  Trp           45.67±29.24      58.19±40.62                                               71.62±41.18                                                                                        26.08±25.18[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                        57.23±38.40[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Tyr           73.75±55.55      197.70±62.38[a](#tfn6-ott-8-1989){ref-type="table-fn"}    134.86±56.24[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}   101.49±51.79[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                       206.64±52.43[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  Val           132.85±47.04     191.68±69.10[a](#tfn6-ott-8-1989){ref-type="table-fn"}    136.68±59.08[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                             194.82±55.68[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}                                             185.31 ±64.79[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}
  C0            32.62± 13.67     22.32±11.78[a](#tfn6-ott-8-1989){ref-type="table-fn"}     12.69±7.30[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}     8.89±6.98[a](#tfn6-ott-8-1989){ref-type="table-fn"}[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                21.87±11.85[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  C2            19.81±11.18      37.66±13.57[a](#tfn6-ott-8-1989){ref-type="table-fn"}     21.34±10.33[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                              17.30±10.22[b](#tfn7-ott-8-1989){ref-type="table-fn"}                                                                                        36.88±13.64[a](#tfn6-ott-8-1989){ref-type="table-fn"}[c](#tfn8-ott-8-1989){ref-type="table-fn"}[d](#tfn9-ott-8-1989){ref-type="table-fn"}
  C5:1          0.04±0.02        0.02±0.01[a](#tfn6-ott-8-1989){ref-type="table-fn"}       0.02±0.01[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                                0.02±0.01[a](#tfn6-ott-8-1989){ref-type="table-fn"}                                                                                          0.02±0.01[a](#tfn6-ott-8-1989){ref-type="table-fn"}

**Notes:**

*P*\<0.05 (significant difference vs the control group);

*P*\<0.05 (difference vs before chemotherapy);

*P*\<0.05 (after chemotherapy \[+21 days, +14 days\] vs chemotherapy \[+1 day\]);

*P*\<0.05 (after chemotherapy \[+21 days\] vs\[+14 days\]).

###### 

AST, ALT, TTP, and PFS in eight patients with hypocarnitinemia compared with control group during chemotherapy

  Group                                 Total   AST                                                      ALT                                                       ALB          mTTP (months)                                          PFS (months)
  ------------------------------------- ------- -------------------------------------------------------- --------------------------------------------------------- ------------ ------------------------------------------------------ -------------------------------------------------------
  Hypocarnitinemia                      8       60.79±33.29[a](#tfn10-ott-8-1989){ref-type="table-fn"}   104.70±29.78[a](#tfn10-ott-8-1989){ref-type="table-fn"}   40.67±4.61   4.62±1.72[a](#tfn10-ott-8-1989){ref-type="table-fn"}   6.06± 1.61[a](#tfn10-ott-8-1989){ref-type="table-fn"}
  Normal chemotherapy (control group)   22      40.89± 17.31                                             57.19±27.60                                               41.88±6.02   8.2±3.04                                               8.97±3.08
  *P*-value                                     0.009                                                    0                                                         0.314        0.001                                                  0.003

**Note:**

*P*\<0.05 (significant difference vs the control group).

**Abbreviations:** AST, aspartate amino transferase; ALT, alanine aminotransferase; TTP, time to progression; PFS, progression-free survival; RR, response rate; ALB, serum albumin; mTTP, median TTP.

###### 

RR and adverse reactions in eight patients with hypocarnitinemia compared with control group during chemotherapy

  Group                                 Total   RR                                             Diarrhea   Nausea   Vomiting   Myelosuppression
  ------------------------------------- ------- ---------------------------------------------- ---------- -------- ---------- ------------------
  Hypocarnitinemia                      8       1[a](#tfn12-ott-8-1989){ref-type="table-fn"}   4          4        3          3
  Normal chemotherapy (control group)   22      14                                             3          6        4          5
  *P*-value                                     0.035                                          0.06       0.38     0.34       0.64

**Note:**

*P*\<0.05 (significant difference vs the control group).

**Abbreviations:** AST, aspartate amino transferase; ALT, alanine aminotransferase; TTP, time to progression; PFS, progression-free survival; RR, response rate; ALB, serum albumin; mTTP, median TTP.

###### 

AST, ALT, TTP, and PFS in 12 patients with hypercitrullinemia compared with control group during chemotherapy

  Group                                 Total   AST             ALT           ALB          mTTP (m)    PFS (m)
  ------------------------------------- ------- --------------- ------------- ------------ ----------- -----------
  Hypercitrullinemia                    12      50.91 ± 19.01   63.72±37.16   42.52±5.53   7.37±3.65   8.45±3.62
  Normal chemotherapy (control group)   18      43.05±26.76     73.96±33.38   40.92±5.74   7.16±2.90   8.02±2.68
  *P*-value                                     0.131           0.177         0.194        0.863       0.711

**Abbreviations:** AST, aspartate amino transferase; ALT, alanine aminotransferase; TTP, time to progression; PFS, progression-free survival; RR, response rate; ALB, serum albumin; mTTP, median TTP.

###### 

RR and adverse reactions in 12 patients with hypercitrullinemia compared with control group during chemotherapy

  Group                                 Total   RR   Diarrhea   Nausea   Vomiting   Myelosuppression
  ------------------------------------- ------- ---- ---------- -------- ---------- ------------------
  Hypercitrullinemia                    12      6    3          5        3          4
  Normal chemotherapy (control group)   18      9    4          5        4          4
  *P*-value                                     1    1          0.461    1          0.678

**Abbreviations:** AST, aspartate amino transferase; ALT, alanine aminotransferase; TTP, time to progression; PFS, progression-free survival; RR, response rate.
